Earnings call transcript Q2 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Quanterix Corporation Q2 2023 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that, today's conference is being recorded.

to Ed conference Relations. Joyce like first to now today speaker VP would hand over the your I of Investor the yours. floor Ed, is

Ed Joyce

today's President Stacy, is Financial and Officer. you, and morning. Chief me Thank good Mike Doyle, Masoud CEO and on Toloue of Quanterix With call

within forward-looking assumptions Before I'd Private our We statements Securities contain the the Litigation on are achieve disclosed Investor remind based Reform statements. section of call. like meaning on our intentions Act. you not things. may will These a on forward-looking few the available management's we call will information plans beliefs will US and statements, the be Today's expectations the begin, the website. of as forward-looking call The available actually date of be or and in to of recorded of and Resources

and Forward-looking future or that actual the cause our factors statements uncertainties, materially forward-looking implied involve from other or be known assumptions achievements and statements. expressed may performance to or different performance unknown results by risks, achievements results any

that analysis GAAP face and the non-GAAP uncertainties and Commission. financial has of supplement in to evaluate trends a uses its most on company operating certain financial Securities comparison these in provided and we with risks performance are meaningful Exchange To our described for manner company's presented statements recent Management basis, measures. The the filings, a in non-GAAP period-to-period measures that business. allows the

of their issued financial in with operating with, our as are are non-GAAP information accordance appendix in directly to be Investors substitute forth most to presentation and non-GAAP other earnings and the in comparable to such The useful measures review here release conjunction that, for posted results today. the the a in should measures company's period the presented believes important in the not website to encouraged financial the GAAP and reconciliation the presented company set to current comparing of these measures information considered The are assessing results financial GAAP. performance.

over I'll that, turn the call With to Masud.

Masoud Toloue

Good morning. Ed. you, Thank

results, growth. transformation to effort the of improvements getting improvements year. a operational corporate talented and made our started to people, strong by made acknowledging Before while our start magnitude capabilities Quanterix these last the is would set and team progress with the execution The foundation testament solid continuing intense I has long-term have to future the of like drive to

our financial quarter This those in became apparent more performance. business and strides

XX% margin prior of revenue increases quarter demand, XX% our year versus Second increased lab Accelerator increased improvement. respectively. seeing and We're XX% gross to consumables with million $XX significant driven with to XX.X% sequential business, customer non-GAAP and and by strong

positively bottom corporate line impacting is Our transformation also performance. already

full be This $XXX we full million, redevelopment our in percentage to quarter, we the XXs. gross achieved cash accelerating increased margin our XXXX flow range guidance and progress year $XXX the of in revenue With a milestone. high breakeven year million to non-GAAP

range to cash less $XX this year. $XX now burn to million expect of the also in be We million estimate and

following a quarters margins. track. ago business potential on at prime We're high-quality remind scale process the of To objective strategic the technology assays maximizing delivering strong last Simoa year now our remain corporate our transformation with our we in review initiated and a and two transformation with you, the of of

modern will and These impact that at implementation progress Quanterix, efforts our further our flow. systems new newly in at which remains operations remarkable. lines. launching Work positive SKUs have processes is long-term growth cash directly The drive and our of includes scaled and team made intensity future assay kit

correlated this with This Alzheimer's phosphorylated-tau blood-based of disease. diagnostic measures tau XXX. platform our test process. presence a aid a the amyloid has disease to In Using plasma Alzheimer's the protein of been an of high-sensitivity early July, we pathology test in launched hallmark positively brain, biomarker LucentAD, in isoform protein

LucentAD with indicate or unlikely points pathology. amyloid possible cut to provides measurements

approval to quick the test scalable therapies of this recent and screening. Leqembi, we access With the first of one promising for enable disease, will Alzheimer's anticipate

attention focused infrastructure effort deploy these Alzheimer's There's tests. of building disease as and around a well and we on as education lot will global provider patient on

your were Moving bring that announcements to like two Association recent I'd events. from There the to Alzheimer's notable International Conference to attention.

diagnose recommended the Alzheimer's First, Institute National biomarkers use Alzheimer's detect for new disease. guidelines the the Association by to of and on blood Aging, were and

listed All on Simoa. available are biomarkers of the

lot This numbers Simoa blood-based those testing. expensive large high studies of our makes LucentAD invasive cost-effective Alzheimer's systems and technology and between spinal to people amyloid the methods scalable of suspected within scans. have being demonstrated such like testing analysis screen of by to PET fluid a Numerous correlation more require in measured able as with sense cognitive biomarkers

lab to in position lab, and the of Simoa in the puts global with a in biomarker listed That Any testing for guidelines along anywhere running the every order CLIA Alzheimer's help can infrastructure the scale the great globe us platform begin reach needed build our today. therapies.

possibility data Gothenburg for Simoa blood the Sweden a Second, in study Researchers demonstrating Alzheimer's home used presented a from finger prick. technology test spot to biomarkers. collected dry was biomarkers at for from from cards the for collection blood of University

blood and results a samples micro to testing showed NFL blood. not card shipped and of liters. p-tauXXX, samples correlation all including without lot GFAP. a were temperature control facility Starting We're high p-tauXXX, biomarkers drawn tested regular of for That's to tens talking

would significant as pretty incredible an the for platform and be for promise events. capabilities Although potential ultrasensitive this Simoa study, over demonstrates early our providers a collection, home as advance blood the was of patients well traditional as it a test

neurological in expect number require cascade early will will we and monitoring, And routine biomarkers disease-modifying which a most need diagnosis therapies. to of emerging of ultrasensitivity identify decade, This these blood.

with this seeing discussed, light neurofilament injury for of last As attention or NfL chain we neuro we're approval conditions. measuring quarter Tofersen increasing of biomarker the

forward study data work levels. robust foundation data set However, by This as significant age. for to reference and the a provide comprehensive between a was pediatric a go-to adults normal NfL use set Neurology, data NFL Lancet This NfL a clinical in Simoa of levels will for for step and in the a neuro and need management further Recently test produce there's blood and vary set establishes published Simo children. enabled a adolescents for measurements. conditions

Moving of patients, XX validation better clinical the for platform efforts study consideration an positive regulators. Alzheimer's quarter collaboration to of which a readout with our this done our by we diverse and important a trial, achieved prospective demographic clinical in The potential represent entire base and aimed global BioHermes foundation. had sites physicians the top XXXX-patient to line was study

to is XXX and our announce correlation with objective scans filing work between to positive our IBD was leasing PET our the This study show to both a AD for the primary FDA. support and expected supported pleased LDT new amyloid I'm achieved.

before moment Now, a to turn to I the take over call Mike, I recap. to want

Mike? accelerated performed the and the transformation work is complete because on organization focus, the understand bearing expect we Discoveries and will not platform. treat at and of that while neurological Quanterix. the test Our yet discipline next currently Quanterix' way people Simoa XX that corporate be years disease much in levels of change will gains execution of all of at we

Mike Doyle

Masoud. Thanks

For your Slide X. for along, starting reference I'm those on following

XXXX. for was of revenue from million, XX% second increase the an quarter XXXX $XX the of quarter Our of total second

and agreement deal. Ultra with million million revenue includes an DX onetime $X China related our related Abbott revenue to quarter's $X.X in for Limited This to license

of We decline in instrument quarter, over XX% $X.X increase XX% a second second XXXX. was million, over XXXX. had Within an $XX.X revenue, revenue second of quarter of product million revenue of the quarter the of the product

science instrument see As to described last global life providers, other quarter we to capital pressures on and macroeconomic similar continue purchases.

decline versus our the year of compared XX% prior or up X% this the consumable million, second quarter. $X Offsetting quarter and revenue increased last to

capacity. demand allowed While have improvements as and to we quality, address we for to asset continue manage us have production made that consumables we increase

quarter, million other the revenue driven Services. for or and was from increasing the $XX.X of $X demand XX% by XXXX, Accelerator for million strong quarter second Services

offering, -- to Our on and be when CapEx valuable pharma purchases. experienced biotech a continue valuable customer particularly Services Accelerator pressure

second the of until to purchasing second year, and half While we further and we the in the patterns. do instruments pharma Accelerator to returned decline both expect normal for half, don't expect consumables offset Services fully biotech for

for gross Now, quarter. the let's on move margin to

profit million compared million Our of second XXXX. for quarter $X.X of XX.X% XX.X% was gross to XXXX, the and second quarter GAAP margin the $XX.X and in

or profit shipping in it which performance. of gross within last the quarter gross and million in better for of we're second within very XX.X% cost $XX.X includes second non-GAAP margin, XX.X% sales the reflected product as progress to and sold goods our costs with was million and handling margin Our quarter targeted than SG&A redevelopment in $X.X instead pleased year. is of compared expenses, Overall,

of the from $XX.X million to overall expenses second XXXX. GAAP of in in operating $X quarter XXXX XX.X% quarter declined Our million the second

$X.X net the in million of the our declined second in million second restructuring $XX.X from program, to interest the our in to quarter impact loss XXXX, redevelopment XXXX, improvements Our from of improved and income. due of quarter XXXX

We the our mix, Moving decrease quarter healthy cash expense We is improvement. $XXXXXX balance. quarter, essentially revenue driven operating net X. management. gains, QX about on during on of We second a in cash slide million the had no a which to from $XXX.X efficiency cash, ended burn and with cash, burned cash small by

for and to sheet remain excellent opportunistic well balance remains positioned in inorganic Our investments shape investment. and make internal be

slide XX. Let's to which turn on is highlighted guidance,

mentioned, range $XXX $XXX Masoud expect to million. guidance million our the our to million revenues from of we're now a for of million $XXX increasing in We As $XXX to XXXX. range be previous

our are for efforts. well margin Due anticipated still we're revenue we continue to our managing full adjusting of a year the program As demand reminder, redevelopment redevelopment and as mix in our assay XXXX, as outlook. shipments we part our as our

do execute ability headwind assay plan. GAAP in year, low to our now high confident the with XXs of new launch half second of some on the the with gross margin and the in kit be our gross We anticipate XXs. SKUs, percent the anticipate non-GAAP feel be We our to percent to but in margin impact

cash in million, to a for previous our in to the last $XX year full significant We of burn expect range be guidance. year our from million improvement the $XX

turn to we your Masoud, questions. take will I back it before over Masoud?

Masoud Toloue

want leadership Thank to regard transition financial you, Mike. our update plans. I provide an in to

clearly thrilled to an announced, team. planning 'XX found someone is time in to join a we and amazing retire for CFO that join new And searching it's to exciting to Quanterix. we've previously I'm early say been Mike As our and

announcement August Mike until making Director Finance, our for So, formal supporting tomorrow a transition to his official strategic growth morning is March. transition the time, retirement Executive we'll and XX. to of that going At set be is

us a the moment the So made the Mike pivotal look business. We're has guidance, He service, solid Quanterix, what's has specifically period, his of transformation take the dedication position. transition of past lasting impact role thankful want strong for in months. leadership a the to I two on had to years played to a put in over in our appreciative and his coming financial acknowledge has and forward

Operator, let's take questions. some

Operator

Thank you.

now ahead with Instructions] go [Operator Puneet will Our Leerink Partners. question-and-answer your question. Souda comes of conduct please We from the first Puneet, session. question

Puneet Souda

if XQ. there Hey, that I could could, and is if first higher of set. keep also guide second quarter implies then a thanks. to here, We year congrats funding I still the for largely good it and working margins? on the a gross know LucentAD guide, the Masoud, XQ your the a street. Mike, the on biomarker in -- thanks step really of again And and ask end luck want here. known clarify one or Mike is look you assumptions guide you the the maybe just bit down little the on understood at part mind in to on the on and half? to follow-up have line full something and and the we you on that else the in ought the if go well situation what's conservatism top great biotech ahead. I I and obviously with on I that on about Is maybe talked

Mike Doyle

Sure.

I think things. of a couple

quarter. this we obviously think, onetime had in some revenue I

And I quarter. really $XX.X it a I at the XX, million at about look look so when at

we're we of redevelopment which quarters our Masoud think I the is -- last So, when still effort it's and last is balancing going big this to really couple into push. get

we're there. a of looking room goal sure we're don't that. what out we But we So and I how we've just ourselves there exceed than that that we've impacting revenues. expect would sort some to is of noise bit make anything chatted see given there's our about to it. our trying else think Clearly, little at that's

Masoud Toloue

macroeconomic this Puneet situation. – right. backdrop a that's there's think I Yeah, clearly, we of

Mike that what highlighted conservative half. the in a said, of in been the that think Mike see And then lines of production to lot I implementation want pretty on And happens we call to able as second offset effectively. processes we've that the about. key be we'll

Puneet Souda

it. Got

marker Okay. well beyond you this see if can then you Lucent, that this as XXX, p-Tau when an and we'll as p-Tau one let's on LDT, involves XXX as -- platform it. a And do IVD XXX said p-Tau in an marker going think that, AβXX, to is to eventually clarify GFAP potentially say then both wondering AβXX when more have XXX and and maybe

to final into able said, be that then to launch think you'll market like an could eventually IVD? trying what when the just do and So understand LDT as look you

Masoud Toloue

great question, a Puneet. It’s

So we our plan have -- year. to LDT this is XXX

as And that the testing. then just you as our exists about LucentAD talk we'll that our already know after work. announcement the complete your intend of then test, we series multimarket to your And Lucent of Quanterix future other the some multimarket about an some test RUO to on point, including to offering. at question we clinical So today offering, into add trial

expanding about algorithm look we all we're patients. a just XXX. we results study with Bio-Hermes to pathology markets that with study. looking at We're amyloid at talked to And then where multi-marker, ADDF of and the have large you the an that at So -- we have exhaustive that mentioned, with for looking very specific

along regulatory clinical the these is we'll So again FDA, trial that's the side to also intention upcoming. on findings. submitting with And be our the that

Puneet Souda

bit you the for Got it. LDT for little that the for then IVD the talk last potentially of your me. and validation Super. diagnostic with Can a And about And assays? currently as one well. level assay for is you have needed the what

other the you of of scalability validation Just Thank want a of those both How these for sort have you Donanemab sort sense to do drugs needed if you. of get market? validation scalability, are positioned required? a those scalability Leqembi be you and and readiness that of on from point if of rapid that a might assays, how think what things -- And and level as get assays is view? point view

Masoud Toloue

Thanks, Puneet. Yes.

of over step shown have to XXX, I talking RUO robustly amyloid a that -- years, XXX, the on NfL let's over publications We're would that and basis. We last shown. foundation peer-reviewed we're the these several is working GFAP with So, -- incredible kind when pathology. This we say talking trials. assays. And really correlation about of together foundation publications and of first the prospective talk we're one the about that's biomarkers our hundreds that -- hundreds further, that's the take clinical

underserved an trial for US that the P-tauXXX is used support site XX over trial XX So example, to was were LDT of samples from the our Bio-Hermes populations.

filings. support to that's key and and tests Critical more And future robustness imaging we about AD for have sufficient And data, clinical do and more patients as each support other continue of probably imaging to backing that and And to and we to and for for XXX, we look as unimpaired MCI at and Alzheimer's hear data data each that and regulatory mild in cognitively of at the tests expect LDT. our looked we CSS. patients LDT. are compare is our our we news. testing, the to that the you'll the think we an out also come to And

to And scale by scaling clinical that the then are be do about number So to these going way we We the utility in perspective, guidelines. from assays you as we great critical. ongoing work have a going a scale perspective, be to therapy. possible. heard is that's a from trial as team. for you entry And robust think test one, a testing how critical Blood-based the believe

get and Simoa to of for their do guideline All platform testing. be and the markers we'd a a would running to globally today in up support them lab purchase in who Simoa new lab the run can

take building of on level The thousands in some here basis. infrastructure. samples we our for we can do support that CLIA think a will second And of global this weekly laboratory

So we have I plan. a think

have and this on good We trial a go-to-market clinical plan good a plan NAD.

the So several next we're really excited months. about

Puneet Souda

Thanks. good. Super, Okay.

Operator

Our of Kyle go Genuity. comes next ahead your question from Mikson with question. Kyle, Canaccord

Kyle Mikson

questions. on this for Thanks on progress guys. the quarter. on Hey, redevelopment congrats taking Congrats the the And program.

how now customers? On to the customer program able those and the RUO I improved. that and Masoud, approach wanted just biopharma you've to the customers ask assays your kind been how convey has differs of to how reproducibility, of response scalability the that And between

Masoud Toloue

look it's would demand for that hitting Accelerator, thanks never We you that our at levels Kyle, Kyle I Hey, has the say company kind or whether words. our seen we're I – the consumables, if before. – mean our Yes. of

is what leaving I Quanterix, and a hands. product it's would – to able manage the we're in that, and at it's that's say that customers' So the if ensure product a quality doors

I'd we've we're that. And accretive those also several that our quarters, and margins. door ensure going the at then the next SKUs great doing So to leaving to done over say, a job scalable that are

So quarters customers And today, good I providing of to themselves. left, think Accelerator work right getting through and couple the assays of but work program. for speak we're results we're solid our now

Kyle Mikson

then following great. on That BioHermes. up the And Okay. just was

then did approval? we with are you the timing for the trial? readouts So done completely comment that And for diabetes on

Masoud Toloue

Yes.

complete are our with we XXX study. So

supported the have that our the that for and And LDT we test. trial pTau-XXX filing, so BioHermes exists both data our FDA

we're already website. on on that those to in and data publication set. and testing specs sense on Lucent the we're intention probably news to AD regard our future BioHermes. you peer-reviewed results can biomarkers for our the XXX, there'll data for see is And taking but But other going that is with be with more the what do next at Now a look

that And is with support multi-marker. been on the about then the test, and this going second be that's to multi-marker the that’s global test global to trial talking ADDF, we've trial

any haven't We mentioned sort on filings. of regulatory timing

we about As the a more breakthrough have with we've talked progress as designation FDA you for doing work know and XXX we

Kyle Mikson

it maybe you chatting Awesome. want look and on kind on And Mike if then next forward Okay. and the to comment about congrats to of steps this guess I soon.

of in cash cash million On is which you net great. have it's prioritization flow cash, breakeven mean, fantastic. of I the was quarter $XXX the

kind the like achieve at that I positive that pulled revenue. do the in ask of up that up will how really could guess, you range all those maybe. crank going reach forward? I using now, drive to XXX point $XXX or forward revenue cushion -- something the past That's that you want and anticipate you or think to growth or guess I for flows I million $XXX you LucentAD scale million what's you earlier Is cash given kind to now? kind of spending mean, pushed estimated I is -- of just lines? cash Could along

Mike Doyle

Colin. Yes. Thanks,

-- for I still positive updating and on that we I'd demonstrated been super a our very think, from in And look first, cash think we probably consistently, I running focused haven't we the were Look we've assay adjusted think it's we current happy be, projection keep say, redevelopment. and February. with flow in place I standpoint, ahead what guidance will the are quarter. would I is, financial our longer-term say,

more is DX. organic -- it in business, you've for to what also Lucent touched I Kyle of and on to investments some start investments you're going in see funding think the

expect we're cash going to I see go out. So

going we things we CapEx I down looking organically half and second that a the redevelopment, half do it's the ability because on road And year inorganically to the pick assay help we of think was year. cash the up have the grow. number accelerate as both our of focused of first light in the in us will at the we're to stayed

updating So February breakeven for -- be our and the like we'll I flow as update said, guidance cash probably call on we'll probably in well. and targets

Kyle Mikson

Perfect.

it. good. Sounds guys. Appreciate Thanks

Mike Doyle

Kyle. Thanks,

Masoud Toloue

Kyle. Thanks,

Operator

Sykes Matt, Sachs. next Goldman [Operator ahead question. from comes question Instructions] with with Matt your please Our go

Matt Sykes

Mike. you. on congrats just It's question the Maybe and on a question the first working with congrats And next great my taking quarter. for been Mike Thanks you for chapter.

range could You've talked still and given any kind on as quarter, next just that about digits, XXXX of year? for of growth the line for quarter different And double-digit a mean previously about raised last it a top are things. you this double lot of clarity guidance kind thinking

Mike Doyle

Yes, it can.

obviously had of our guidance You're suggest accelerate point core It's product is there. And good I and would the to -- a that we've right we're think Matt. we're -- because the our there. is from quarter goal

forecast accelerate double-digit are feels a off fleshed intent to haven't to of specific today. our clearly and But we what We out is like. where about looks get more like yet XXXX

more good So going in to and say on core But is are that's probably I clearly, February this the on all and now, now. obviously of about but products the good in we're digit right year, we look again be giving like. going a expect right year we're feeling to we'll view what sit and it robust where pretty right place now a we're cracking double-digit double

Matt Sykes

the prepared Thanks if for just But what Abbott. mentioned from of in received that. just it. color provide the the a little just doing I missed Abbott color? past on with collaboration then maybe Can apologies some more revenue and bit in that. you a Got more this you little you're I've about you comments the And

Mike Doyle

Actually license deal. Abbott is Yes. an the an old of expiration

time an in a funds not recognizing active. that's license so ago some it Essentially it's revenue. So for now expired we're received we

So new with not it's activity per se Abbott.

of $X we venture were that shares from the Ultra-DX in reflection the China. then And issued is Ultra-DX a million in

not onetime repeat. those they're in both to So, are going instances revenue and

Matt about So, favorable points this quarter just basis XXX perspective impact there. by margin you to give they a in some way

Matt Sykes

one Got Masoud. for it. And then one you just last

and technology that do finger kind in that think if terms maybe what And line logistics happen? into could time were about the also in longer incorporated could but term blood for cards. your could looked accessibility it talk that what prick the how just study and potentially you at You of be be talked about of to the that testing you

Masoud Toloue

Yes, absolutely Matt.

collection of But in that on say heels on you And and is to global infrastructure. a draw excitement sort a near XX% methods. and this up place you the scale got let's we're blood concept do where all this traditional globally. draw US say bringing can population of think global blood of the of the keep just So, while

transportation where And ability places are by all temperature quantification we're excited that do issues. those have. storage And low all there demonstrated are this what remote the a of and that to centrifugation biomarkers lot of was really we about the collection study

this a so can care in screening And trials. we see as and monitoring tool therapeutic in secondary

to access as and going of expanding concept monitor be underserved able for is which easy So, as to therapies an response storage way. in population therapeutic trials to important future the progression treatment well being to

coming a home. in So, you a draw blood someone do have and smart the don't for you regular can basis on

the a and small and early population. days in So, cohort population was study the it's the

So, that. incredibly want CSF. promising say I the But do to data pet correlations and on with

interesting think that of very and within I we're be in detecting study what a about or the next that could there's this year lot biomarkers. these for so could And work the next so excited come

sort then And is final draw hundreds of -- this of microliters. blood mean goes a I make hundreds show point we're talking the and to that I'll

what's required the talking sensitivity is of we're that microliters and microliters a card blood tens need that to of tens for detect platform about those in has to enable testing. and tens Now, high

again, the about And excited very prospect these we're results. so, of

Matt Sykes

Got it. Thanks very guys. much

Masoud Toloue

Matt. Thanks

Operator

Dan with from Cowen. Brennan comes our final question And

Dan Brennan

the Thanks for question.

Operator

Dan?

Dan Brennan

Alzheimer's, the missed how in speak the Maybe placements APAC. of if back can the placements on in expectations are what one instrument to one on you Congrats the softness on I was Just quarter? And quarter. to it. due much year throughout Sorry. Sorry,

distributor called think in a I XQ. out you

some there. maybe color Just

Mike Doyle

XX% quarter that's the XXs for late started which to XX%. placements -- high-XXs mean, I Dan. and run were Historically, a last year low placements to placements QX -- us. we've Yeah. were were is in net drift it

So we're down.

Asia in issue was QX. think Pac I our

think broadly as board. I across well, I seeing I think did we're and more the mentioned it really Masoud

and America, it, effect seeing impacting in I Europe think just we're there's us. CapEx a North Pac. on in And Asia macro that's

in actually year did performed Pac better than Asia the quarter they ago. a

So it bounces around.

are is, we otherwise getting good the Now, for would news purchase. people from who still us get revenue

more think I to are instrument. as think through lab, purchasing running Masoud I Accelerator an opposed folks referenced, our

So we're which -- it's we right I we're going expect up year in instruments think from as XXXX, to and But balance now to of encouraging. it's don't building we're and it's degrade That's the be -- is going to of broader pick going projecting kind at I improves, see macro a to our we soft. more out how the where are. expect something normal. return a

Masoud Toloue

Yeah. capabilities their that pharma or pressure macroeconomic lab. to is we biotech we've our outsource Dan, kind more these the one seen really we and of when equipment see or that, unique companies to have of of Accelerator capital challenge, tend work more

that for of more of seeing expect to clearly we're this and And continue the half second the year.

R&D before also future those there's we outsourcing and the in -- it's you less purchase to pressure platforms. a work. And So Accelerator customers expect buy, of lot back tried will us is both those but once for come

Dan Brennan

maybe Quanterix? say over you Alzheimer's Great. kind Thank check you and list. and look would be bigger to if are of a could was the like the you we just -- for And out maybe the opportunity watch the of maybe what markdowns materializing kind little months throughout, this key a mentioned then most a for on next that would just What kind that. is get but progress important picture one XX see bit to of just apologize,

Masoud Toloue

Yeah.

on it's think and I also Dan, our how test and filing. readout -- this by the Hermes IBD the our supporting about LDT talked we So

that I think -- earlier question a to was Puneet it related XXX asked. on the call

platforms is biomarker And is so right? XXX detect XXX. Simoa you that can't just important, pretty that's think measure any a you I of that platform, can on one the

interest the for important. so And is demand and XXX

of come And about therapies importance one shows the the identify the hearing is as can out, you reasons that works. these you're earlier the these therapy of better we're patient a drugs that data and the seeing cascade, kind in because disease

is XXX of those early markers. so one And

patient perspective. better the of and or better a from And rule-in a cohort you a standpoint -- screen so diagnosis, from a get better a it looks can

So we're excited about very that.

think big a that will milestone. be I

multimarket. is might to And getting we a patients near cognitive Can that but result. a Can have "Hey these the differential second then multi-marker a we symptoms, on diagnosis? a more information the I get do get on I'm And negative result. they're asking use negative

" what program build we're And talking for to is so about intensive behind solutions an what? here patients. Now

I think And so milestones. those I two next two as the would key view

the externally, incredible. then if biomarker the and at biomarkers And of is promise look think I blood some guidelines, you the

so biomarkers And more just instead of from scan. more blood PET we of the towards and and about tap diagnosis not in months there be expect a spinal but the patients their next a discussion to adoption or screen, several more

of I for the as key sort those view So and kind milestones field. would three us for areas of

Dan Brennan

Great. Thanks lot. a

Masoud Toloue

Dan. Thanks,

Operator

I questions today's am participating. call. time. you This conference concludes showing at for Thank this no further

may You now disconnect.

Quanterix (QTRX) 8 Aug 232023 Q2 Earnings call transcript